Lung Cancer: A Global Health Challenge

Lung cancer, also known as bronchogenic carcinoma, originates in the lung tissue or bronchial passages and stands as one of the most formidable health challenges of our time. It is the most frequently diagnosed cancer worldwide, responsible for over 12% of all cancer cases. More alarmingly, it remains the leading cause of cancer-related deaths, claiming millions of lives each year.

Lung cancer primarily falls into two major categories: Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell Lung Carcinoma (SCLC).

• NSCLC is the more prevalent form, accounting for the majority of cases. It typically progresses at a slower rate, offering a broader window for diagnosis and treatment.
• SCLC though less common, is known for its aggressive nature. It tends to grow and spread rapidly, often requiring swift and intensive medical intervention.

Recognizing the type of lung cancer is crucial, as it directly influences treatment strategies and outcomes. Early detection significantly increases the chances of survival. Next Generation Sequencing enhances the detection, and management of lung cancer by providing detailed genetic insights that inform personalized treatment approaches, improve monitoring strategies, and contribute to ongoing research efforts by allowing for the simultaneous analysis of multiple genes, providing a comprehensive view of the tumor's genetic landscape, quantify TMB, which may predict responses to immunotherapy.

G2M FOCUS Lung – Overview

The G2M FOCUS Lung is a somatic NGS assay, aimed to screen important and guideline recommended genes and fusions (like ALK, ROS1, NRGQ, RET) associated with various lung carcinomas like NSCLC (ALK, ROS1, NTRK, RET etc.) and Lung adeno-carcinomas (EGFR, MET, KRAS, BRAF etc.). The genes are selected based on the guidelines of the NCCN, CAP, ESMO, and FDA.